Today, Novartis CEO Vas Narasimhan announced the company’s financial results for the first quarter of 2018.
Leprosy is an ancient disease that currently infects more than 200 000 people each year. For more than three decades, Novartis and the Novartis Foundation has been working to reduce the incidence of leprosy, and the Novartis Foundation recently helped establish the Global Partnership for Zero Leprosy in an effort to eliminate the disease.
Novartis is one of 73 companies included in the 2017 Water A List by CDP, the nonprofit global environmental disclosure platform.
The third Novartis Social Business stakeholder dialogue took place on November 21 in Basel.
RAND Corporation and the Moran Company issued reports discussing the cost savings associated with biosimilars.
The event will take place on November 21 in Basel.
Individualized CAR‑T therapy uses a patient’s own immune system to fight certain types of cancers.
Newly released survey findings shed light on the daily challenges associated with cataracts and the emotional benefits of improved vision after surgery. Nearly all survey respondents said they would recommend cataract surgery based on their personal experiences.
More than 300 million people live with asthma globally, and 6 million do not adequately control their symptoms. In a new European survey of nearly 1,000 severe asthma patients, 88% reported the condition impacted their daily lives, and almost the same amount (84%) said asthma limited their physical activity.
Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.
This site is intended for a global audience.